Zynex — Q4 2024 Earnings Presentation
17 slides from Zynex's earnings presentation, Mar 11, 2025
Slide 1: NASDAQ: ZYXI Investor Presentation
NASDAQ: ZYXI Investor Presentation December 2024
Slide 2: Forward Looking Statement
Forward Looking Statement This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are ba
Slide 3: Corporate Overview
Corporate Overview Zynex is a medical technology company that manufactures and sells non-invasive medical devices for pain management, rehabilitation and patient monitoring. NASDAQ: ZYXI Share Price1 $7.17 • We deliver opioid-free pain management solutions & non-invasive patient Market Cap1 $222.3M
Slide 4: Corporate Purpose
Corporate Purpose Zynex provides prescription We are committed to being strength pain relief & the world’s premier pain exceptional service management provider Our mission is to improve the quality of life of patients suffering from debilitating pain or illnesses by providing the highest technology
Slide 5: Total Addressable Market
Total Addressable Market $4.6B $950M Pain & Rehabilitation Incontinence Treatment Stroke Rehab Hemodynamic Monitoring Pulse Oximetry Sepsis $3.6B Electrotherapy1 PATIENT MONITORING4 • Over 1.5 billion worldwide suffering from chronic pain2 • >6,000 hospitals and >900,000 staffed beds in the U.S.5 •
Slide 6: Electrotherapy
Electrotherapy Addressable Market & Product Portfolio $950M 1 Pain & Rehabilitation Incontinence Treatment Stroke Rehab ELECTROTHERAPY Nexwave Rehabilitation Other Products Pain Relief, Muscle Rehabilitation Products Inwave & Neuromove 1) Emergen Research report titled “Electrotherapy Market by trea
Slide 7: NexWave
NexWave Prescription Strength Electrotherapy Opioid-Free Pain Treatment • 84% of patients were able to reduce medication use1 • Nearly half reduced medication consumption by 50%1 Benefits • Relieves pain, augments healing, alleviates swelling through increased blood circulation, prevents muscle disu
Slide 8: Building a Strong Distribution Network
Building a Strong Distribution Network Direct Sales Patients Physicians & Therapists Insurance Plans • Direct sales force is growing rapidly with • HMO and PPO private incentives for productivity and efficiency insurance plans Efficient • Physician relationships include orthopedics, • Patient’s carr
Slide 9: Patient Monitoring
Patient Monitoring Addressable Market & Product Pipeline $3.6B1 Hemodynamic Monitoring Pulse Oximetry Sepsis PATIENT MONITORING * * CM-1500/1600 NiCOTM & HemeOxTM Sepsis FDA Cleared Noninvasive Wireless Laser-based Noninvasive CO-Oximeter (NiCO ) Noninvasive Sepsis Monitor Fluid Monitoring System &
Slide 10: Patient Monitoring Product Pipeline
Patient Monitoring Product Pipeline Hemodynamic Monitoring Pulse Oximetry Sepsis Monitoring Noninvasive, continuous fluid NiCOTM Global Health Concern monitoring • 48M cases and 11M deaths per Noninvasive CO-Oximeter uses Early Warning System year, globally1 laser technology to measure • Determines
Slide 11: Growth Trajectory
Growth Trajectory Launch in new vertical: Drive Value Through Patient Monitoring Organic Growth and M&A • $3.7 billion market • Drive market adoption of • FDA Clearance of CM- differentiated monitoring 1600 Monitor in June 2023 solutions • Higher average selling • Increase international sales Today
Slide 12: Financial Performance
Financial Performance Revenue Gross Margin ($M) (%) 81% 81% 79% 79% 80% 79% 80% $184.3 $192.4 $158.2 $130.3 $80.1 $45.5 $31.9 2018 2019 2020 2021 2022 2023 2024 2018 2019 2020 2021 2022 2023 2024 Consistently high gross margins 2024 Revenue growth of 4% imply a defensible business model NASDAQ: ZYXI
Slide 13: Financial Performance
Financial Performance Diluted EPS Adj. EBITDA ($) ($M) $28.1 $0.44 $0.44 $26.7 $22.3 $0.29 $0.28 $0.27 $0.24 $13.7 $12.1 $10.9 $10.9 $0.09 2018 2019 2020 2021 2022 2023 2024 2018 2019 2020 2021 2022 2023 2024 Consistent profitability despite investments in a direct sales team and buildout of monitor
Slide 14: Management Team
Management Team Thomas Sandgaard Dan Moorhead Anna Lucsok Founder, Chairman & CEO Chief Financial Officer Chief Operating Officer • Chairman, President, and CEO of Zynex since founding the • Responsible for all finance and accounting functions. • Previously served as VP of Reimbursement and Sales co
Slide 15: Investment Highlights
Investment Highlights Company valued on established electrotherapy business. Patient monitoring business is pre-revenue with transformative growth potential Outstanding financial performance • 33% Revenue CAGR from 2019 – 2024 ($45.5M $192.4M) • SaaS-like gross margins of ~80% • Solid balance sheet:
Slide 16: www.zynex.com
Investor Relations Company Contact Brian Prenoveau, CFA Dan Moorhead MZ Group Chief Financial Officer, Zynex 561-489-5315 ir@zynex.com ZYXI@mzgroup.us www.zynex.com 9655 Maroon Circle, Englewood, CO 80012
Slide 17: EBITDA Reconciliation
EBITDA Reconciliation $ in thousands For the Three Months Ended Sept 30, 2024 2023 Use of Non-GAAP Financial Measures This presentation includes the non-GAAP financial measure of Adjusted EBITDA, which Adjusted EBITDA: differs from financial measures calculated in accordance with accounting principl